×
HOME

13th Adriatic Congress of Pharmacoeconomics and Outcomes Research with focus on CEE

APRIL 24-26, BUDAPEST, HUNGARY

Dear Colleague,

It is our great pleasure to invite you to participate in the 13th Adriatic Congress of Pharmacoeconomics and Outcomes Research with focus on CEE, which will be held at Continental Hotel Budapest in Budapest, Hungary, on April 24-26, 2025, and will be organized by the Section for Pharmacoeconomics and Outcomes Research of the Croatian Society of Clinical Pharmacology and Therapeutics, Croatian Medical Association in partnership with the Hungarian Health Economics Association (ISPOR Hungary Chapter).

The main objective of this year congress is to intensify and enhance professional and scientific discussions and collaboration between various stakeholders on the following topic:

STRENGHTENING VALUE-DRIVEN HEALTHCARE DECISIONS TO IMPROVE PATIENT-CENTRED
AND SOCIETALLY ORIENTED OUTCOMES ACROSS CEE COUNTRIES


After several years in which we have been focusing to problem identification, assessment, and measurement, mostly around equitable patient access to innovative health technologies, and identifying the gaps to more developed EU countries, we have switched our focus to finding solutions.

During our 15 years journey, the capacity of CEE countries to focus on solutions has improved in public, private and academic sectors. Additionally, and most importantly, patient engagement in this process have also significantly improved, so we believe all pre-requisites have now been met to start focusing on the most optimal solutions for which we need all stakeholders to be at the same table, discussing, agreeing, and implementing these solutions, especially in the following area, being also the sub-topics of this year’s congress:

  • Integration of JCA to national P&R processes in CEE
  • Patient empowerment in HTA and healthcare decision making
  • Societal impact of health technologies
  • Importance of RWE in healthcare decision making  
  • Evolving HTA methodologies for digital health technologies
  • Diverging or converging access timelines in CEE - implications to healthcare outcomes
  • Importance of horizon scanning for securing timely healthcare decisions Real World Data and Information Systems


However, the full congress agenda will also comprise other important topics as well, such as development of healthcare policies, pharmaceutical pricing and reimbursement, comparative efficacy studies, outcomes research, value of health and health interventions, and many others. Preliminary program is attached for your reference.

Based on previous experience and recognized regional importance of this congress, we are expecting around 160 participants, attending in person, from more than 12 countries of Central, South and East Europe, from different fields, personally contributing and working together for the success of this congress and positive impact it has on fostering collaboration at national and regional levels.

We encourage your participation by submitting research podium and poster papers. As every year, we will organize several plenary sessions, round table discussion, issue panels, and research presentations.

It is important to note that we, as the organizers, will ensure participation of a wide range of stakeholders within the health care: the healthcare professionals (local, regional and international), members of academia, different associations, regulatory and payer authorities, politicians, and last but not least the pharmaceutical industry.

The overarching goal of the Congress is to advance public health care policies in order to maximize societal welfare and optimize diffusion of and access to innovative health care technologies, so that patients can reach their full life and health potential.

We are cordially looking forward to seeing you soon in Budapest, Hungary!
With kindest regards, and on behalf of Congress Organizing Committee,

Prof. Zoltán KALÓ, PhD

Congress Co-Chair    

Prof. Dinko VITEZIĆ, MD, PhD

Congress Co-Chair    

Professor of Health Economics, Center for Health Technology Assessment, Semmelweis University

Lead Partner, Syreon Research Institute, Budapest

President, Section for Pharmacoeconomics and Outcomes Research, Croatian Society for Clinical Pharmacology and Therapeutics